Elutia Inc.

Elutia Inc. (ELUT) priced its initial public offering on Oct 8, 2020 at $17.00 per share, within its $16.00–$18.00 range, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $173.8M. Piper Sandler was lead-left underwriter, joined by TD Cowen, Cantor and Truist. Latham & Watkins advised the company and Davis Polk advised the underwriters.

Elutia Inc. is a commercial-stage regenerative medicine company creating products for patients undergoing surgery, mainly those receiving implantable medical devices. Its tissue processing platforms yield products for implantable electronic device and cardiovascular, orthopedic and spinal repair, and soft tissue reconstruction markets, sold in part through relationships with Boston Scientific and Medtronic.

Status

IPO

Ticker

ELUT

Exchange

Nasdaq Global Market

Priced

Oct 8, 2020

IPO price

$17.00

Price range

$16.00–$18.00

Market cap at IPO price

$173.8M

First filed

Sep 14, 2020

Underwriters

Piper Sandler, TD Cowen, Cantor and Truist

Company counsel

Latham & Watkins

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

MD

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.